Blog | Cost of Care

Digestive diseases led increase in treatment costs over the last two decades, analysis finds

Blog | Cost of Care

Digestive diseases led increase in treatment costs over the last two decades, analysis finds

Cancer is the lone disease category for which treatment costs decreased during a 23-year period.

A new study quantifies the extent to which treating disease has become increasingly expensive since just before the turn of the century.

The insurance navigator analyzed U.S. Bureau of Labor Statistics healthcare data spanning 1999 to 2022. After accounting for inflation, the analysis found the average cost of treating disease increased from $1,159 to $1,712 during the time frame.

Among specific diseases, the leading drivers of cost growth were:

  • Intestinal infections: 427% increase ($134 to $570)
  • Tonsillitis: 419% increase ($392 to $1,644)
  • Diseases of the mouth excluding dental: 416% increase ($76 to $317)
  • Head, neck and trunk wounds: 408% increase ($146 to $595)
  • All other digestive diseases: 385% increase ($1,492 to $5,736)

“Three out of five diseases to see the greatest percent growth are conditions of the digestive system,” the report notes.

A key factor appears to be an increase in inpatient hospitalizations and emergency department visits for those conditions, suggesting severe cases are becoming more common.

Among categories of disease, “symptoms, signs and ill-defined conditions” led the way in cost growth, increasing by 2.4 times during the study period. That was followed by dental diseases (2.2), injury and poisoning (2.18), infectious and parasitic diseases (2.16) and genitourinary diseases (2.15).

Some conditions become less expensive

Some of the most pervasive diseases have declined significantly in cost, potentially owing in part to technological advances that allow treatments to be delivered in less intensive settings. Another factor could be changes in coding practices, which may have led to an increase in milder cases of some diseases.

The biggest drops in cost were seen for:

  • Diabetes with complications: 78% decrease ($1,424 to $314)
  • Heart attack: 61% decrease ($10,250 to $4,047)
  • Arterial blood clot: 48% decrease ($5,735 to $2,995)
  • Anemia: 40% decrease ($1,209 to $725)
  • Acute bronchitis and other types of lung disease: 33% decrease ($1,668 to $1,210)

Advancements in preventive care may have reduced the severity of circulatory and blood-related disorders, analysts noted.

Among disease categories, only cancer dropped in cost — and not by much. The average cost to treat all cancers in 2022 was 10% lower than in 1999. Preventive care and screenings likely are a key aspect of that improvement, analysts said.

About the Author

Nick Hut

is a senior editor with HFMA, Westchester, Ill. (

Sign up for a free guest account and get access to five free articles every month.


Related Articles | Cost of Care

News | Cost Effectiveness of Health

HFMA's Annual Conference: Joe Fifer calls on healthcare organizations to find ways to better address holistic health issues

Healthcare stakeholders must embrace a broader concept of health to enhance the welfare of their communities, according to a pair of talks Monday at HFMA’s Annual Conference.

News | Pricing

Hospital prices increasingly are coming under a microscope

Newly issued reports and policy recommendations are examining hospital prices in the context of high healthcare costs.

Blog | Strategic Partnerships Mergers and Acquisitions

Healthcare News of Note: New CMS data set makes hospital and skilled nursing facility ownership changes more transparent

Healthcare News of Note for healthcare finance professionals is a roundup of recent news articles: CMS releases a new report on healthcare provider ownership, a new report examines the consequences of the pandemic for Black Americans, and 34% of nurses plan to leave their current job in 2022.

News | Healthcare Business Trends

Latest financial metrics for hospitals show reasons for optimism but also persistent challenges

Hospital financial performance partially recovered in March as patient volumes returned to something closer to normal after a significant downturn during the omicron wave.